Bayer's MRI Contrast Agent Gadovist Could Get "Lower-Risk" Designation

But the sponsor will have to convince an FDA advisory committee that the drug's unusual dosing will not cause medication errors in a crowded class.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Pink Sheet